Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells
View/ Open
Author
Sundberg, Thomas B.
Choi, Hwan Geun
Song, Joo-Hye
Russell, Caitlin N.
Hussain, Mahmud M.
Graham, Daniel B.
Khor, Bernard
Gagnon, John
O’Connell, Daniel J.
Narayan, Kavitha
Dančík, Vlado
Perez, Jose R.
Reinecker, Hans-Christian
Gray, Nathanael S.
Schreiber, Stuart L.
Xavier, Ramnik J.
Shamji, Alykhan F.
Published Version
https://doi.org/10.1073/pnas.1412308111Metadata
Show full item recordCitation
Sundberg, T. B., H. G. Choi, J.-H. Song, C. N. Russell, M. M. Hussain, D. B. Graham, B. Khor, et al. 2014. “Small-Molecule Screening Identifies Inhibition of Salt-Inducible Kinases as a Therapeutic Strategy to Enhance Immunoregulatory Functions of Dendritic Cells.” Proceedings of the National Academy of Sciences 111 (34): 12468–73. https://doi.org/10.1073/pnas.1412308111.Abstract
Genetic alterations that reduce the function of the immunoregulatory cytokine IL-10 contribute to colitis in mouse and man. Myeloid cells such as macrophages (M Phi s) and dendritic cells (DCs) play an essential role in determining the relative abundance of IL-10 versus inflammatory cytokines in the gut. As such, using small molecules to boost IL-10 production by DCs-MFs represents a promising approach to increase levels of this cytokine specifically in gut tissues. Toward this end, we screened a library of well-annotated kinase inhibitors for compounds that enhance production of IL-10 by murine bone-marrow-derived DCs stimulated with the yeast cell wall preparation zymosan. This approach identified a number of kinase inhibitors that robustly up-regulate IL-10 production including the Food and Drug Administration (FDA)approved drugs dasatinib, bosutinib, and saracatinib that target ABL, SRC-family, and numerous other kinases. Correlating the kinase selectivity profiles of the active compounds with their effect on IL-10 production suggests that inhibition of salt-inducible kinases (SIKs) mediates the observed IL-10 increase. This was confirmed using the SIK-targeting inhibitor HG-9-91-01 and a series of structural analogs. The stimulatory effect of SIK inhibition on IL-10 is also associated with decreased production of the proinflammatory cytokines IL-1 beta, IL-6, IL-12, and TNF-alpha, and these coordinated effects are observed in human DCs-M Phi s and anti-inflammatory CD11c(+) CX(3)CR1(hi) cells isolated from murine gut tissue. Collectively, these studies demonstrate that SIK inhibition promotes an anti-inflammatory phenotype in activated myeloid cells marked by robust IL-10 production and establish these effects as a previously unidentified activity associated with several FDA-approved multikinase inhibitors.Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:41461176
Collections
- FAS Scholarly Articles [18176]
Contact administrator regarding this item (to report mistakes or request changes)